Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Construction in Progress (2023 - 2025)

Abvc Biopharma (ABVC) has disclosed Construction in Progress for 3 consecutive years, with $7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Construction in Progress changed N/A year-over-year to $7.4 million, compared with a TTM value of $7.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $691900.0, up 21.54% over the prior year.
  • Construction in Progress was $7.4 million for Q3 2025 at Abvc Biopharma, roughly flat from $7.4 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $7.4 million in Q2 2025 and bottomed at $529121.0 in Q2 2024.
  • Average Construction in Progress over 3 years is $2.5 million, with a median of $691900.0 recorded in 2024.
  • The sharpest move saw Construction in Progress grew 21.54% in 2024, then soared 1298.55% in 2025.
  • Year by year, Construction in Progress stood at $569278.0 in 2023, then rose by 21.54% to $691900.0 in 2024, then surged by 969.52% to $7.4 million in 2025.
  • Business Quant data shows Construction in Progress for ABVC at $7.4 million in Q3 2025, $7.4 million in Q2 2025, and $691900.0 in Q1 2025.